Cost-effectiveness of pneumococcal conjugate vaccination in Croatia

Highlights • PCV is not cost-effective in Croatia based on benefits in children alone. • PCV could prevent ∼100 hospital admissions for children <5 years each year. • PCV could prevent ∼1 death in children <5 years each year. • PCV13 introduction would cost US$ 1376 per case averted. • PCV10 i...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 33; pp. A209 - A218
Main Authors:	Vučina, V. Višekruna, Filipović, S. Kurečić, Kožnjak, N, Stamenić, V, Clark, A.D, Mounaud, B, Blau, J, Hoestlandt, C, Kaić, B
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 07-05-2015 Elsevier Limited
Subjects:	Allergy and Immunology Child, Preschool Cost control Cost-Benefit Analysis Cost-effectiveness Croatia Croatia - epidemiology Decision-making Demography Ear diseases Economics Evidence-based medicine Health care Health Policy Health services Humans Immunization Immunization Programs Infant Infant, Newborn Life expectancy Models, Statistical Mortality Pneumococcal Pneumococcal Infections - economics Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - economics Pneumococcal Vaccines - immunology Price cuts Public health Sensitivity analysis Streptococcus pneumoniae Vaccination - economics Vaccination - methods Vaccine Vaccines Croatia Pneumococcal Decision-making Vaccine Cost-effectiveness Evidence-based medicine Croatia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Highlights • PCV is not cost-effective in Croatia based on benefits in children alone. • PCV could prevent ∼100 hospital admissions for children <5 years each year. • PCV could prevent ∼1 death in children <5 years each year. • PCV13 introduction would cost US$ 1376 per case averted. • PCV10 introduction would cost US$ 1164 per case averted.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.12.043